These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33657135)

  • 41. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
    Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
    EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.
    Tragni V; Mercurio I; Paoletti DP; Onofrio A; Laera L; Cafferati Beltrame L; Sgobba MN; Guerra L; Volpicella M; De Grassi A; Elia G; Pierri CL
    J Med Virol; 2023 Jun; 95(6):e28875. PubMed ID: 37338047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.
    Walter JD; Scherer M; Hutter CAJ; Garaeva AA; Zimmermann I; Wyss M; Rheinberger J; Ruedin Y; Earp JC; Egloff P; Sorgenfrei M; Hürlimann LM; Gonda I; Meier G; Remm S; Thavarasah S; van Geest G; Bruggmann R; Zimmer G; Slotboom DJ; Paulino C; Plattet P; Seeger MA
    EMBO Rep; 2022 Apr; 23(4):e54199. PubMed ID: 35253970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
    Yan R; Wang R; Ju B; Yu J; Zhang Y; Liu N; Wang J; Zhang Q; Chen P; Zhou B; Li Y; Shen Y; Zhang S; Tian L; Guo Y; Xia L; Zhong X; Cheng L; Ge X; Zhao J; Wang HW; Wang X; Zhang Z; Zhang L; Zhou Q
    Cell Res; 2021 May; 31(5):517-525. PubMed ID: 33731853
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.
    Stefan MA; Light YK; Schwedler JL; McIlroy PR; Courtney CM; Saada EA; Thatcher CE; Phillips AM; Bourguet FA; Mageeney CM; McCloy SA; Collette NM; Negrete OA; Schoeniger JS; Weilhammer DR; Harmon B
    MAbs; 2021; 13(1):1958663. PubMed ID: 34348076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
    Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.
    Long Y; Song S; Luo F; Han X; Hu C; Wang Y; Li S; Wang W; Zhang H; Zhang B; Li T; Jin A
    Biochem Biophys Res Commun; 2021 Sep; 571():152-158. PubMed ID: 34325131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
    Chen X; Gentili M; Hacohen N; Regev A
    Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection.
    Tomassetti F; Nuccetelli M; Sarubbi S; Gisone F; Ciotti M; Spinazzola F; Ricotta C; Cagnoli M; Borgatti M; Iannetta M; Andreoni M; Calugi G; Pieri M; Bernardini S
    Int Immunopharmacol; 2021 Oct; 99():108013. PubMed ID: 34339963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
    Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
    Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.